Work

Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study

Year: 2022

Type: article

Study design: Observational Study

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2022.04.003

Authors: Yumeng Zhang, Lauren Duncanson, Jason Brayer, Frederic Reu, Doris Hansen, Melissa Alsina, Taiga Nishihori, Jose Ochoa-Bayona, Hien Liu, Kenneth Shain, Zachary Thompson, Rachid Baz, Brandon Blue

Institutions: University of South Florida, Moffitt Cancer Center

Language: English

Topic: Amyloidosis: Diagnosis, Treatment, Outcomes

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Sanofi, Celgene, Karyopharm Therapeutics, Moffitt Cancer Center, Merck Sharp and Dohme, National Cancer Institute

Awards: G362094, G4551976579, G8135003176, Moffitt Cancer Center Support Grant

OpenAlex ID: W4226484326

FWCI: 0.163

Cites: 16

Cited by: 5

Related to: 10